Angela Neubauer

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG1 Instead of IgG4.

Subcutaneous Allergen Immunotherapy With Hypoallergenic Bet v 1 Compared to Conventional Extract: Poorer Blocking Antibody Capacity Dominated by IgG1 Instead of IgG4.

Journal: Allergy

Published: January 22, 2025

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response.

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response.

Journal: EBioMedicine

Published: September 11, 2019

Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma.

Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma.

Journal: American journal of respiratory and critical care medicine

Published: August 23, 2018

Comparing Proteolytic Fingerprints of Antigen-Presenting Cells during Allergen Processing.

Comparing Proteolytic Fingerprints of Antigen-Presenting Cells during Allergen Processing.

Journal: International journal of molecular sciences

Published: April 27, 2017

Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.

Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.

Journal: The Journal of allergy and clinical immunology

Published: April 20, 2017

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients.

Epicutaneous allergen application preferentially boosts specific T cell responses in sensitized patients.

Journal: Scientific reports

Published: April 05, 2017

Endolysosomal protease susceptibility of Amb a 1 as a determinant of allergenicity.

Endolysosomal protease susceptibility of Amb a 1 as a determinant of allergenicity.

Journal: The Journal of allergy and clinical immunology

Published: November 19, 2016

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.

Journal: EBioMedicine

Published: July 31, 2016

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.

Journal: The Journal of allergy and clinical immunology

Published: March 31, 2016

Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.

Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments.

Journal: The Journal of allergy and clinical immunology

Published: April 17, 2015

Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.

Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy.

Journal: International archives of allergy and immunology

Published: August 07, 2014

Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients.

Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients.

Journal: The Journal of allergy and clinical immunology

Published: July 05, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026